This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): MDX-018, HuMax-IL8, HuMax-IL-8
Description: HuMax-Inflam is a high affinity fully human IgG1,k antibody directed towards IL-8. IL-8 is a mediator of inflammation, a chemoattractant for white blood cells called neutrophils, as well as a factor in angiogenesis. HuMax-Inflam blocks binding of IL-8 to neutrophils and inhibits neutrophils from migrating towards sites of inflammation via a process known as chemotaxis. HuMax-Inflam also inhibits IL-8 induced neutrophil activation. In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice.
Genmab and Medarex
In June 2001, Genmab and Medarex entered into a collaboration agreement to develop HuMax-Inflam. Under the agreement, the parties will share the cost associated with the pre-clinical and clinical development of the product and will share the commercialization rights and royalties.
Under the collaboration with Genmab on HuMax-Inflam, Medarex has the right to 100% of all revenues and profits in Asia. Outside of Asia, Medarex and Genmab share in the revenues and profits on a 50/50 basis, subject to certain payments that Genmab owes Medarex with respect to milestones and royalties on MDX-018.
Bristol-Myers and Medarex
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
In September 2009, Bristol-Myers Squibb completed its acquisition of Medarex.
Genmab and...See full deal structure in Biomedtracker
Partners: Genmab A/S
Additional information available to subscribers only: